Europe Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel

Description

List of Tables

The Europe infectious disease therapeutics market was valued at US$ 35,451.86 million in 2022 and is expected to reach US$ 49,108.21 million by 2030; it is estimated to register a CAGR of 4.2% from 2022 to 2030.

Increasing Focus on Funding and R&D in Infectious Disease Therapeutics Drives Europe Infectious Disease Therapeutics Market

Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.

In order to create solutions for the most important health issues that Europe and the rest of the world are currently encountering, the European Union is investing in research, technology, and innovation. The European Commission has led the way in promoting research, particularly that related to immunity to and management of infectious diseases. Between 2007 and 2019, more than US$ 4.3 billion (4 billion) was allocated to the study of infectious diseases. Further, Horizon Europe, the upcoming (2021-2027) EU funding initiative for research and innovation (R&I), will carry on supporting R&I for infectious diseases, notably those associated with poverty, those that are neglected, and those that are (re-)emerging.

Horizon Europe is a program dedicated to supporting research and innovation. To bridge barriers across regions and establish tangible collaborations, the program places a strong emphasis on ensuring cooperation between universities, scientific communities, industry, especially small and medium-sized firms, and individuals. The Health Work Programme outlines funding options under Horizon Europe for research related to infectious diseases and pandemic preparedness and response. Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth.

Europe Infectious Disease Therapeutics Market Overview

The Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global infectious disease therapeutics market and is estimated to register a notable CAGR during 2022-2030. The region has an increased incidence of chronic viral diseases and a high demand for developing new anti-viral drugs. With US$ 15.79 billion funded from 2007 to 2019 through the 7th Framework Program and Horizon 2020 and the US$ 1.1 billion pledged for COVID-19 research, Europe plays a crucial role in funding and coordinating research on infectious diseases. According to The Robert Koch Institute, in Germany, ~400,000 to 600,000 patients suffer a hospital-acquired infection each year, among which 10,000-15,000 die. Typical problems for healthcare providers are surgical site infections, urinary tract infections, and pneumonia. The demand for anti-infective agents in Germany is growing significantly, attributed to the rising geriatric population, the increasing prevalence of chronic viral diseases, and the growing demand to produce new molecules for viral therapeutic areas to fulfill unmet conditions. Germany is one of the leading nations for anti-viral agent manufacturing and growth potential in Europe due to the high quality of its finished products. For instance, Atriva Therapeutics GmbH, a biopharmaceutical company, developed ATR-002 to treat patients with COVID-19 in a Phase II Study to block viral propagation of SARS-CoV-2. Therefore, due to the abovementioned factors, the market is expected to grow significantly in the country.

Europe Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Europe Infectious Disease Therapeutics Market Segmentation

The Europe infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the Europe infectious disease therapeutics market is segmented into anti-viral, anti bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the Europe infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the Europe infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the Europe infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Europe infectious disease therapeutics market.

Product Code: BMIRE00030411

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Infectious Disease Therapeutics Market - Key Market Dynamics

4.1 Europe Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Infectious Disease
- 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
- 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
- 4.4.1 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
- 4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Europe Analysis

5.1 Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Europe Infectious Disease Therapeutics Market Analysis - by Drug Class

6.1 Overview
6.2 Anti-Viral
- 6.2.1 Overview
- 6.2.2 Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
- 6.3.1 Overview
- 6.3.2 Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
- 6.4.1 Overview
- 6.4.2 Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
- 6.5.1 Overview
- 6.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Infectious Disease Therapeutics Market Analysis - by Indication

7.1 Overview
7.2 HIV
- 7.2.1 Overview
- 7.2.2 HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
- 7.3.1 Overview
- 7.3.2 Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
- 7.4.1 Overview
- 7.4.2 Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
- 7.5.1 Overview
- 7.5.2 Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
- 7.6.1 Overview
- 7.6.2 HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Infectious Disease Therapeutics Market Analysis - by Route of Administration

8.1 Overview
8.2 Oral
- 8.2.1 Overview
- 8.2.2 Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
- 8.3.1 Overview
- 8.3.2 Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
- 8.4.1 Overview
- 8.4.2 Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Infectious Disease Therapeutics Market Analysis - by Distribution Channel

9.1 Overview
9.2 Hospital Pharmacies
- 9.2.1 Overview
- 9.2.2 Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
- 9.4.1 Overview
- 9.4.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Infectious Disease Therapeutics Market - Country Analysis

10.1 Europe Infectious Disease Therapeutics Market
- 10.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.1 Overview
  - 10.1.1.3 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.1 Germany: Infectious Disease Therapeutics Market Breakdown, by Drug Class
    - 10.1.1.3.2 Germany: Infectious Disease Therapeutics Market Breakdown, by Indication
    - 10.1.1.3.3 Germany: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
    - 10.1.1.3.4 Germany: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
  - 10.1.1.4 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.4.1 Overview
  - 10.1.1.5 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.5.1 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Drug Class
    - 10.1.1.5.2 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Indication
    - 10.1.1.5.3 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
    - 10.1.1.5.4 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
  - 10.1.1.6 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.6.1 Overview
  - 10.1.1.7 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.7.1 France: Infectious Disease Therapeutics Market Breakdown, by Drug Class
    - 10.1.1.7.2 France: Infectious Disease Therapeutics Market Breakdown, by Indication
    - 10.1.1.7.3 France: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
    - 10.1.1.7.4 France: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
  - 10.1.1.8 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.8.1 Overview
  - 10.1.1.9 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.9.1 Italy: Infectious Disease Therapeutics Market Breakdown, by Drug Class
    - 10.1.1.9.2 Italy: Infectious Disease Therapeutics Market Breakdown, by Indication
    - 10.1.1.9.3 Italy: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
    - 10.1.1.9.4 Italy: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
  - 10.1.1.10 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.10.1 Overview
  - 10.1.1.11 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.11.1 Spain: Infectious Disease Therapeutics Market Breakdown, by Drug Class
    - 10.1.1.11.2 Spain: Infectious Disease Therapeutics Market Breakdown, by Indication
    - 10.1.1.11.3 Spain: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
    - 10.1.1.11.4 Spain: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
  - 10.1.1.12 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.12.1 Overview
  - 10.1.1.13 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.13.1 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Drug Class
    - 10.1.1.13.2 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Indication
    - 10.1.1.13.3 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
    - 10.1.1.13.4 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Organic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Pfizer Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Gilead Sciences Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Shionogi & Co Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Bayer AG
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 BioCryst Pharmaceuticals Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 GSK Plc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 AbbVie Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Merck & Co Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Astellas Pharma Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners